Related Experiment Video
Updated: Dec 10, 2025

Preparation of Naringenin Solution for In Vivo Application
Published on: August 10, 2021
Comparative Analyses of Bioavailability, Biotransformation, and Excretion of Nobiletin in Lean and Obese Rats
Man Zhang1, Yanping Xin2, Konglong Feng3,4
1Department of Food Science, Rutgers University, 65 Dudley Road, New Brunswick, New Jersey 08901, United States.
Abstract:
Nobiletin, one of the prevalent polymethoxyflavones in citrus peels, was reported to possess various health benefits. We conducted the excretion study and pharmacokinetics study of nobiletin via oral administration and intravenous injection and 15 day consecutive dosing study using the high fat diet-induced obese rats and their lean counterparts. By comparing the demethylated metabolite profiles in the urine and feces, gut microbiota demonstrated greater biotransformation activity on nobiletin than the host. The absolute oral bioavailability of nobiletin in lean (22.37% ± 4.52%) and obese (18.67% ± 4.80%) rats has a negligible statistically significant difference (P > 0.05). However, a higher extent of demethylated metabolites was found in the feces and plasma of obese rats than lean rats (P < 0.05). Moreover, the consecutive dosing of nobiletin might lead to a higher extent of demethylated metabolites in the plasma and in feces. These results suggested that gut microbiota played important roles in nobiletin metabolism.
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Drug Dosing: Obese Patients
Bioavailability Study Design: Absolute Versus Relative Bioavailability
Bioavailability Study Design: Healthy Subjects Versus Patients
Factors Influencing Bioavailability: First-Pass Elimination

